• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Perspective Therapeutics Inc.

    4/16/25 4:31:24 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care
    Get the next $CATX alert in real time by email
    DEFA14A 1 def_-_notice_internet_20.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

     

    Preliminary Proxy Statement

     

     

     

    ☐

     

    Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

     

     

    ☐

     

    Definitive Proxy Statement

     

     

     

    ☒

     

    Definitive Additional Materials

     

     

     

    ☐

     

    Soliciting Material under to § 240.14a-12

     

    PERSPECTIVE THERAPEUTICS, INC.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

     

    No fee required.

     

     

     

    ☐

     

    Fee paid previously with preliminary materials.

     

     

     

    ☐

     

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     


     

    img149680737_0.jpg

     

    Your Vote Counts! PERSPECTIVE THERAPEUTICS, INC. 2025 Annual Meeting Vote by May 27, 2025 11:59 PM ET PERSPECTIVE THERAPEUTICS, INC. 2401 ELLIOTT AVENUE, SUITE 320 SEATTLE, WA 98121 V69414-P26720 You invested in PERSPECTIVE THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 28, 2025. Get informed before you vote View the Notice and Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 14, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote in Person at the Meeting* May 28, 2025 8:30 a.m., Pacific Time 2401 Elliott Avenue Suite 320 Seattle, Washington 98121 *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

     


     

    img149680737_1.jpg

     

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. We encourage you to access and review all of the important information contained in the proxy materials before voting. Voting Items 1. To consider and vote on a proposal to elect five directors named in the Proxy Statement, each to hold office until the Company’s 2026 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified: Nominees: 01) Lori A. Woods 02) Heidi Henson 03) Robert Froman Williamson, III 04) Frank Morich, M.D., Ph.D. 05) Johan (Thijs) Spoor 2. To consider and vote on a proposal to ratify the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025. 3. To consider and vote on a proposal to approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. Board Recommends For All For For Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V69415-P26720

     


    Get the next $CATX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CATX

    DatePrice TargetRatingAnalyst
    3/13/2025$10.00Buy
    H.C. Wainwright
    3/7/2025$15.00Sector Outperform
    Scotiabank
    11/25/2024$24.00 → $5.00Buy → Neutral
    BofA Securities
    10/24/2024$20.00Buy
    UBS
    10/1/2024$25.00Outperform
    Wedbush
    9/25/2024$21.00Buy
    Truist
    7/25/2024$24.00Buy
    BofA Securities
    5/9/2024Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CATX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Spoor Johan M. bought $59,673 worth of shares (26,676 units at $2.24), increasing direct ownership by 59% to 59,383 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 6:44:41 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Director Williamson Robert F Iii bought $132,151 worth of shares (60,337 units at $2.19), increasing direct ownership by 124% to 108,982 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 5:04:49 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Graham Juan bought $74,946 worth of shares (33,333 units at $2.25), increasing direct ownership by 1,649% to 35,354 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 5:03:59 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Perspective Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $10.00

      3/13/25 7:26:51 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Scotiabank initiated coverage on Perspective Therapeutics with a new price target

      Scotiabank initiated coverage of Perspective Therapeutics with a rating of Sector Outperform and set a new price target of $15.00

      3/7/25 8:03:16 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Perspective Therapeutics from Buy to Neutral and set a new price target of $5.00 from $24.00 previously

      11/25/24 7:39:30 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    SEC Filings

    See more
    • SEC Form SD filed by Perspective Therapeutics Inc.

      SD - Perspective Therapeutics, Inc. (0000728387) (Filer)

      5/19/25 5:02:08 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Perspective Therapeutics Inc.

      10-Q - Perspective Therapeutics, Inc. (0000728387) (Filer)

      5/12/25 4:34:55 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

      5/12/25 4:30:53 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Spoor Johan M. bought $59,673 worth of shares (26,676 units at $2.24), increasing direct ownership by 59% to 59,383 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 6:44:41 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Director Williamson Robert F Iii bought $132,151 worth of shares (60,337 units at $2.19), increasing direct ownership by 124% to 108,982 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 5:04:49 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Graham Juan bought $74,946 worth of shares (33,333 units at $2.25), increasing direct ownership by 1,649% to 35,354 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 5:03:59 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Perspective Therapeutics Inc.

      SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

      11/14/24 6:14:40 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

      SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

      11/14/24 4:05:13 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

      SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

      11/7/24 9:24:55 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Leadership Updates

    Live Leadership Updates

    See more

    $CATX
    Financials

    Live finance-specific insights

    See more

    $CATX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

      SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the appointment of Juan Graham as the Company's Chief Financial Officer (CFO), effective as of January 6, 2025. In connection with the transition, Jonathan Hunt will no longer serve as CFO but will continue serving as the Company's Chief Accounting Officer (CAO). "In less than 18 months, Perspective has delivered initial clinical data for two new potential medicines based on its next generation targeted radiopharmaceutical technology platform,

      1/6/25 8:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

      SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to an updated list of additions to the membership list, considered to be final, as of Monday, June 10th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total mark

      6/12/24 7:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

      Phase I/2a clinical trials initiated: VMT-α-NET for neuroendocrine tumors, and VMT01 for melanoma. Preliminary results from initial cohorts expected by end of 2023.First patient dosed in Phase 1/2a dose escalation trial of VMT01 for treatment of MC1R-positive metastatic melanoma. RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports second quarter financial results for the period end

      8/11/23 8:00:30 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

        Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [212Pb]VMT-α-NET[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested Three of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. First responses for two patients occurred after end of treatment period and are subject to confirmation, in addition to the previously reported patient with confirmed response who remains in response The five other patients in Coh

      1/24/25 7:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025

      SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that an abstract on updated interim results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET (NCT05636618) has been accepted as a poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) taking place on January 23-25, 2025 in San Francisco, CA. The poster presentation entitled "Interim Safety and Efficacy data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs)" will

      1/22/25 7:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

      SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 21-23, 2024 in Chicago. The presentation entitled "Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)" will be p

      11/15/24 4:08:05 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

      First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our clinical stage potential new medicines based on our next generation targeted radiopharmaceutical technology platformEnrollment ongoing for VMT-α-NET, a next generation SSTR2-targeting potential new medicine, with 40 patients enrolled through end of April 2025 in Cohort 2 of the Phase 1/2a trial in neuroendocrine tumorsEnrollment ongoing for VMT01, a first-in-class MC1R targeting potential new medicine, with first patient treated at a new monotherapy dose level in April 2025, following the first patient

      5/12/25 4:36:46 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics to Participate in Upcoming May Investor Conferences

      SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate and be available for one-on-one meetings with investors at the following upcoming investor conferences. Bank of America Global Healthcare ConferenceDate: Tuesday, May 13, 2025Format: Fireside ChatTime: 11:35 a.m. – 11:50 a.m. PT / 2:35 p.m. – 2:50 p.m. ETLocation: Las Vegas, NV 2025 RBC Capital Markets Global Healthcare Conference Date: Tuesday, May 20, 2025Format: Fireside ChatTime: 3:05 p.m. - 3:30 p.m

      5/1/25 7:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

      SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first patient was treated with [212Pb]PSV359 in a Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha (FAP-α). Patients are being selected for [212Pb]PSV359 targeted alpha particle therapy by SPECT imaging with [203Pb]PSV359. "We are excited to explore a new avenue to treat cancers expressing FAP-α wi

      4/29/25 7:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care